Core Viewpoint - Hema Medical (03309) experienced a significant stock price increase of over 8%, reaching HKD 2.09, following the announcement of a global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. for the antiviral drug encequidar [1] Group 1: Company Developments - Hema Medical's subsidiary entered into a tripartite global licensing and collaboration agreement regarding the first P-glycoprotein inhibitor in the virology field [1] - The agreement grants Gilead exclusive global rights to encequidar, while Hema Medical and Hanmi will provide drug supply and share technical knowledge [1] - Hema Medical is set to receive an upfront payment of USD 10 million upon meeting certain conditions and milestones during the agreement period, with potential future payments reaching up to approximately USD 72.5 million [1] Group 2: Financial Implications - Hema Medical will also have the right to receive royalties at a low single-digit percentage on net sales of the drug [1]

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

Group 1 - The core announcement involves a tripartite global licensing and collaboration agreement between a subsidiary of Hema Medical, Gilead Sciences, Inc., and Hanmi Pharmaceutical for the first P-glycoprotein inhibitor, encequidar, in the field of virology [1] - Hema Medical and Hanmi will grant Gilead global exclusive rights to encequidar in the virology field, while also providing drug supply, sharing technical knowledge, and participating as key partners in the project [1] - Upon meeting certain conditions and milestones during the agreement period, Hema Medical will receive an upfront payment of $10 million, with potential future payments reaching up to approximately $72.5 million, along with a low single-digit royalty on net sales [1] Group 2 - Hema Medical is primarily engaged in the development of innovative drugs in the oncology field and is currently researching oral formulations of encequidar [2] - The company is preparing to initiate a Phase 3 global clinical study for the treatment of metastatic breast cancer using oral paclitaxel combined with encequidar, aiming to replace intravenous administration of paclitaxel in chemotherapy [2] - The clinical study is planned to commence by the end of 2025 across multiple centers in the United States, Hong Kong, and New Zealand [2]

Group 1 - The core point of the news is that Hema Medical (希华医药) has entered into a global licensing and collaboration agreement with Gilead Sciences and Hanmi Pharmaceutical for the P-glycoprotein inhibitor encequidar, which Hema Medical holds exclusive global rights outside of South Korea [1] - Under the agreement, Hema Medical and Hanmi will grant Gilead exclusive global rights to encequidar in the field of virology, and they will also provide drug supply and share technical knowledge [1] - Hema Medical is set to receive an initial payment of $10 million, with potential future payments reaching up to approximately $72.5 million, along with a low single-digit royalty on net sales [1] Group 2 - Hema Medical is primarily focused on innovative drug development in the oncology field and is currently researching oral formulations of encequidar [2] - The company is preparing to initiate a Phase 3 global clinical study for the treatment of metastatic breast cancer using oral paclitaxel combined with encequidar, which aims to replace intravenous administration of paclitaxel in chemotherapy [2] - The clinical study is planned to commence by the end of 2025 across multiple centers in the United States, Hong Kong, and New Zealand [2]

Group 1 - The core point of the news is that Hema Medical (希华医药) has entered into a global licensing and collaboration agreement with Gilead Sciences, Inc. and Hanmi Pharmaceutical Co., Ltd. for the antiviral drug encequidar, which Hema Medical holds exclusive global rights outside of South Korea [1] - Under the agreement, Hema Medical and Hanmi will grant Gilead exclusive global rights to encequidar in the field of virology, while also providing drug supply and sharing technical knowledge [1] - Hema Medical is set to receive an upfront payment of $10 million, with potential milestone payments reaching up to approximately $72.5 million, along with royalties based on a low single-digit percentage of net sales [1] Group 2 - Hema Medical is primarily focused on innovative drug development in the oncology field and is currently researching oral formulations of paclitaxel combined with encequidar for the treatment of metastatic breast cancer [2] - The company is preparing to initiate a Phase 3 global clinical study for the oral paclitaxel and encequidar regimen for metastatic breast cancer, with plans to conduct the study at multiple centers in the United States, Hong Kong, and New Zealand by the end of 2025 [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 （股份代號：3309） （於開曼群島註冊成立之有限公司） 自願性公告 最新業務進展 希 瑪 醫 療 控 股 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）董 事 會（「董 事 會」）欣 然 宣 佈，於2025年9月29日，希 華 醫 藥 有 限 公 司（「希華醫藥」）的 一 間 附 屬公司與Gilead Sciences, Inc.（「Gilead」）及 韓 美 藥 品 工 業 株 式 会 社（「韓 美」）就 病 毒 學領域首款P－糖 蛋 白（「P-gp」）抑 制 劑encequidar（希 華 醫 藥 擁 有 該 款 藥 物 在 韓 國 以 外 的 全 球 獨 家 權 利）訂 立 三 方 全 球 授 權 及 合 作 協 議。 根 據 協 議，希 華 醫 藥 及 韓 美 會 將encequidar在病毒學領域的全球獨家權 ...

C-MER Medical Holdings Limited 希瑪醫療控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 3309) N O T I F I C A T I O N L E T T E R 通 知 信 函 24 September 2025 Dear Registered Shareholders, C-MER Medical Holdings Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of T ...

C-MER Medical Holdings Limited 希瑪醫療控股有限公司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號: 3309) N O T I F I C A T I O N L E T T E R 通 知 信 函 Dear Non-registered holders(Note 1) C-MER Medical Holdings Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communications") The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exc ...

2025 INTERIM REPORT 中期報告 Contents | 目錄 | | | --- | --- | | Corporate Information | 2 | | 公司資料 | | | Financial Highlights | 5 | | 財務概要 | | | Management Discussion and Analysis | 6 | | 管理層討論及分析 | | | Interim Condensed Consolidated Statement of | | | Comprehensive Income | 26 | | 中期簡明綜合全面收益表 | | | Interim Condensed Consolidated Statement of | | | Financial Position | 28 | | 中期簡明綜合財務狀況表 | | | Interim Condensed Consolidated Statement of | | | Changes in Equity | 30 | | 中期簡明綜合權益變動表 | | | Interim Condensed Consoli ...

Summary of Key Points Core Viewpoint - On September 17, 28 Hong Kong-listed companies conducted share buybacks, totaling 16.7684 million shares and an aggregate amount of HKD 649 million [1][2]. Group 1: Share Buyback Details - Tencent Holdings repurchased 839,000 shares for HKD 551 million, with a highest price of HKD 663.50 and a lowest price of HKD 645.50, bringing its total buyback amount for the year to HKD 52.707 billion [1][2]. - Hang Seng Bank repurchased 200,000 shares for HKD 23.8014 million, with a highest price of HKD 119.30 and a lowest price of HKD 118.40, totaling HKD 793 million in buybacks for the year [1][2]. - Pacific Shipping repurchased 6 million shares for HKD 14.9526 million, with a highest price of HKD 2.52 and a lowest price of HKD 2.45, accumulating HKD 203 million in buybacks for the year [1][2]. Group 2: Ranking of Buybacks - The highest buyback amount on September 17 was from Tencent Holdings at HKD 551 million, followed by Hang Seng Bank at HKD 23.8014 million [1][2]. - In terms of share quantity, Pacific Shipping led with 6 million shares repurchased, followed by Linklogis Technology and Weigao Group with 2.3 million and 1.9548 million shares, respectively [1][2]. Group 3: Additional Buyback Information - Other notable companies involved in buybacks include Weigao Group, MGM China, and Jitu Express, with respective buyback amounts of HKD 11.4255 million, HKD 7.873 million, and HKD 7.8348 million [2][3]. - The buyback activity reflects a strategic move by these companies to enhance shareholder value amid market conditions [1][2].